| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c29ebbacb306f9b12e38ffad61728746 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
1998-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90f66bdca9fa3e230e9672b83291568c |
| publicationDate |
1998-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2285391-A1 |
| titleOfInvention |
Methods and compositions for treatment of ovarian cancer |
| abstract |
The present invention comprises methods and compositions for a human with ovarian cancer. More specifically, the method comprises administration of a taxane composition over a 96 hour infusion schedule. Importantly, the method of administration allows for reduction of side effects and reduces the chances of multidrug resistance to taxanes. |
| priorityDate |
1997-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |